Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e015065
DOI: 10.1136/jitc-2026-015065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.11.2026. Verfasst von Fabian Junker und 12 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
Despite advances in checkpoint inhibitor (CPI) therapy, a substantial proportion of patients with advanced melanoma experience disease progression, and the capacity of CD8 + cytotoxic T lymphocytes (CTLs) specific for wild-type melanoma-associated antigens to persist and remain functionally inducible after CPI failure is poorly understood. Here we report exploratory translational analyses from the BP41054 Phase I trial investigating the combination of simlukafusp alfa (FAP-IL2v), a tumor stroma-targeted IL-2 variant, with pembrolizumab in CPI-experienced patients with advanced melanoma.MethodsPeripheral blood mononuclear cells from a subset of 33 CPI-experienced patients were profiled at baseline (C1D1_pre) and on treatment (C2D8) using quantitative immunophenotyping and a panel of 28 melanoma-associated peptide–HLA tetramers spanning 14 antigens and multiple HLA alleles. Antigen-specific CTLs were further characterized functionally by ex vivo peptide challenge and interferon (IFN)-γ intracellular staining. Associations with progression-free survival (PFS) were assessed as exploratory endpoints.
Results
Treatment was associated with increased circulating natural killer cells and CD8 + T cells, including effector memory and terminally differentiated effector subsets, as assessed in peripheral blood. CTLs specific for 11 unique peptide-major histocompatibility complexes were identified, with increased frequencies detected during treatment in a subset of patients. These antigen-specific CTLs demonstrated functional activity as indicated by IFN-γ production on peptide challenge, though responses were variable across peptide specificities and patients, and direct cytotoxic activity was not assessed. Signs of incomplete functional rescue, including persistent co-expression of exhaustion markers, were observed. In exploratory descriptive analyses, patients whose antigen-specific CTL diversity increased on treatment had a longer median PFS than those in whom diversity was reduced; with three patients per group, these outcomes are reported descriptively, without formal statistical comparison. Baseline melanoma-associated immunity did not predict clinical outcome.
Conclusions
These hypothesis-generating findings indicate that melanoma-specific CD8 + T-cell immunity persists and remains inducible in CPI-experienced patients, supporting the rationale for strategies that re-engage residual antitumor immunity. Validation in larger cohorts with paired tumor and blood sampling will be required to establish clinical relevance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
- Roche Holdings Inc, South San Francisco, California, USA.
- Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA.
- Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
- Department of Biostatistics, F Hoffmann-La Roche Ltd, Basel, Switzerland.
- Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Junker, F., Darwish, M., Yadav, M., Habigt, C., Bergauer, T., Dejardin, D., Duarte, J., Muñoz-Couselo, E., Bechter, O., Teichgräber, V., Keshelava, N., Kraxner, A., & Charo, J. (2026). Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression. Journal for ImmunoTherapy of Cancer, 14(11), e015065. https://doi.org/10.1136/jitc-2026-015065
Vancouver
Junker F, Darwish M, Yadav M, Habigt C, Bergauer T, Dejardin D, et al. Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression. Journal for ImmunoTherapy of Cancer. 2026;14(11):e015065. doi:10.1136/jitc-2026-015065
BibTeX
@article{Junker2026,
author = {Junker, Fabian and Darwish, Martine and Yadav, Mahesh and Habigt, Christin and Bergauer, Tobias and Dejardin, David and Duarte, José and Muñoz-Couselo, Eva and Bechter, Oliver and Teichgräber, Volker and Keshelava, Nino and Kraxner, Anton and Charo, Jehad},
title = {Enhanced melanoma-specific cytotoxic T-cell expansion and the clinical outcomes with simlukafusp alfa and pembrolizumab following checkpoint inhibitor progression},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e015065},
doi = {10.1136/jitc-2026-015065}
}
EUVIMED